Skip to content

W L Hearn

Metro-Dade County Medical Examiner's Dept., Miami, FL 33136-1133, USA.

3 papers in the library · 234 citations · publishing 1995-1996

Papers

Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.

Life sciences January 1, 1995 D C Mash, J K Staley, M H Baumann et al. 108 citations

Ibogaine, a hallucinogenic indole, is thought to help treat cocaine, stimulant, and opiate abuse, possibly through a long-acting metabolite. This study reports that 12-hydroxyibogamine, a primary metabolite of ibogaine, binds with high affinity to the serotonin (5-HT) transporter and increases extracellular 5-HT levels. In binding assays, 12-hydroxyibogamine was 50-fold more potent at the 5-HT transporter than at the dopamine transporter, while ibogaine and the metabolite were equally potent at the dopamine transporter. Microdialysis showed that 12-hydroxyibogamine dose-dependently elevated extracellular 5-HT, but neither ibogaine nor its metabolite raised dopamine levels in the nucleus accumbens. The metabolite's enhancement of 5-HT transmission may improve mood and reduce drug craving, potentially explaining ibogaine's ability to interrupt drug-seeking behavior.

Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Psychopharmacology September 1, 1996 J K Staley, Q Ouyang, J Pablo et al. 82 citations

Ibogaine, a treatment for drug dependence, is metabolized into 12-hydroxyibogamine (12-OH ibogamine). Both the parent drug and metabolite bind to similar molecular targets, with the highest potency at the cocaine recognition site on the serotonin transporter. The metabolite shows higher affinity at the kappa-1 receptor and lower affinity at the NMDA receptor compared to ibogaine. Micromolar concentrations of both compounds are found in rat brain. The combined actions of ibogaine and its metabolite at key pharmacological targets may alter drug-seeking behavior by modulating reward circuits.

Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry.

Journal of analytical toxicology October 1, 1995 W L Hearn, J Pablo, G W Hime et al. 44 citations

A sensitive method was developed to measure ibogaine and its major metabolite, 12-hydroxy-ibogamine (noribogaine), in biological fluids and brain tissue. The metabolite was identified using gas chromatography-mass spectrometry. The procedure involves solvent extraction, derivatization with ethyl iodide, and cleanup before analysis. Detection limits were 5 ng/mL for both compounds, and quantitation limits ranged from 5 to 10 ng/mL across all tested matrices. Calibration curves were linear from 3 to 1000 ng/mL or ng/g.